Dividend Overview
Dividend Yield
—
Dividend / Share
—
Celldex Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Current Price
$31.34
-3.42%Profile
Valuation (TTM)
Market Cap$2.09B
P/E-7.35
EV—
P/B3.96
Shares Out66.57M
P/Sales2408.99
Revenue$866000.00
EV/EBITDA—
Celldex Therapeutics Inc (CLDX) Dividends
Key Metrics
Market Cap
$2.09B
P/E Ratio
-7.35
Forward P/E
—
EPS
$-3.90
PEG Ratio
-0.16
Book Value
$7.92
Dividend Yield
—
Profit Margin
-32753.58%
ROE
-53.81%
Dividend History
Dividend Safety
CLDX Dividend Analysis
Celldex Therapeutics Inc (CLDX) dividend analysis including yield, payout history, and sustainability metrics.
P/E ratio: -7.35. Profit margin: -32753.58%. Free cash flow: $-213.66M. This page shows Celldex Therapeutics Inc's dividend overview, key metrics, historical payout data, and dividend safety assessment to help income-focused investors evaluate the sustainability of dividend payments.
GoodMoat's dividend analyzer evaluates payout ratios, earnings coverage, and free cash flow coverage to determine how well supported Celldex Therapeutics Inc's dividend payments are. Use this analysis alongside the company's financial statements and quality score to make informed income-investing decisions.